EN
The development of secondary tumor nodules in the lungs is a frequent stage in the progression of various primary cancers, including colorectal carcinoma, renal cell carcinoma, breast cancer, melanoma, and bone sarcomas. Pulmonary tissue contains an extensive network of capillaries through which the entire venous blood volume flows, making it easy for circulating tumor cells to lodge within alveolar capillaries. In such clinical scenarios, structured treatment of lung metastases in Germany relies on thoracic surgical oncology and molecularly targeted systemic therapies. The main goal of German oncologists is to thoroughly evaluate the number, precise localization, and biological activity of metastatic foci to formulate a clear strategy for disease control.
In the past, the detection of distant secondary tumors was regarded as an irreversible stage of disease; however, modern surgical and radiologic technologies have reshaped this perspective. Specialized cancer centers in Germany treat oligometastatic disease—characterized by a limited number of pulmonary nodules—as a manageable condition with long-term survival potential. Treatment plans often combine local surgical interventions with comprehensive care, similar to protocols used for lung cancer treatment in Germany. The application of video-assisted thoracic techniques and precision lasers enables surgeons to remove metastatic lesions while preserving maximum healthy lung parenchyma and maintaining normal respiratory capacity.
Diagnostics and determining resectability of metastases
Before planning any surgical or localized treatment, patients undergo thorough cancer diagnosis in Germany to visualize all chest structures accurately. High-resolution multidetector computed tomography (CT) with intravenous contrast serves as the primary diagnostic tool, capturing cross-sectional slices down to sub-millimeter thickness. According to established pricing benchmarks, a chest CT scan with contrast costs approximately 550 euros. To distinguish active malignant lesions from post-inflammatory granulomas or scar tissue, physicians utilize combined positron emission tomography and computed tomography (PET-CT) with fluorodeoxyglucose. This nuclear imaging technique assesses metabolic tumor activity and detects hidden microscopic foci elsewhere in the body.
When histopathological verification or genetic testing is required, specialists perform advanced endoscopic biopsy procedures. Experienced pulmonologists, such as Dr Wolfgang Gesierich, utilize high-definition bronchoscopy integrated with endobronchial ultrasound (EBUS). This technology allows physicians to obtain tissue samples under real-time visual guidance from deep peribronchial lesions or mediastinal lymph nodes. The collected biopsy specimens undergo cytogenetic and molecular profiling to detect actionable gene alterations, including EGFR, ALK, ROS1, or BRAF mutations, alongside PD-L1 protein expression levels. These molecular findings guide decisions regarding targeted systemic therapy when immediate surgical intervention is inappropriate.
Determining whether pulmonary lesions can be safely resected occurs during a multidisciplinary tumor board (Tumorboard) comprising thoracic surgeons, medical oncologists, radiologists, and pulmonologists. Primary criteria for surgical candidacy include complete control over the primary tumor, the absence of uncontrolled extrapulmonary spread, and adequate pulmonary functional reserve. Specialists evaluate spirometry, lung diffusion capacity, and perfusion scintigraphy results to confirm that remaining lung volume will sustain adequate post-operative breathing. In cases involving multiple metastatic sites, physicians may plan staged surgical procedures, combining thoracic operations with interventions such as liver cancer treatment in Germany.
Resection of lung metastases in Germany: surgical approaches
When surgical resection is indicated, cancer treatment in Germany emphasizes maximum preservation of healthy functional parenchyma. German thoracic surgeons frequently employ minimally invasive video-assisted thoracoscopic surgery (VATS) rather than open thoracotomy. Through two or three small intercostal incisions measuring one to three centimeters, surgeons insert a high-definition video camera and specialized endoscopic instruments. Thoracoscopic resection significantly reduces tissue trauma, minimizes intraoperative blood loss, decreases post-operative pain, and shortens hospital stay, allowing patients to recover faster and proceed to adjuvant therapeutic phases without unnecessary delays.
Specialized German thoracic centers frequently utilize precision laser resection using dedicated diode or Nd:YAG lasers operating at a wavelength of 1318 nanometers. This specific wavelength is optimized for simultaneous parenchymal coagulation, tissue vaporization, and effective hemostasis and aerostasis. Using the laser beam, surgeons can precisely enucleate deep-seated or multiple pulmonary nodules without removing large margins of healthy lung tissue. This technique is invaluable for patients with bilateral or multiple metastatic nodules, as it allows surgeons to remove dozens of subpleural and parenchymal lesions while maintaining vital pulmonary capacity and preventing air leaks.
For lesions located in close proximity to major pulmonary vessels or segmental bronchi, thoracic surgeons perform anatomical segmentectomy or lobectomy. Unlike non-anatomical wedge resections, segmentectomy involves removing specific anatomical segments of the lung while dissecting individual vascular structures and segmental bronchi. Surgical accuracy is monitored during the procedure using intraoperative frozen section analysis of margin tissues, ensuring complete pathological clearance (R0 resection). Modern operating rooms in Munich medical centers enable complex anatomical reconstructions, providing high oncological safety and minimizing the likelihood of local disease recurrence in the operated region.
Conservative and combined treatment methods
For patients with unresectable pulmonary nodules or severe medical contraindications to general anesthesia, stereotactic body radiotherapy (SBRT), including CyberKnife technology, offers an effective alternative to open surgery. SBRT delivers highly concentrated, high-dose ionizing radiation directly to the metastatic nodule with sub-millimeter precision over a few treatment sessions. Real-time respiratory gating systems track chest movement during breathing, continually adjusting the radiation beam to protect surrounding healthy lung parenchyma from radiation damage. Local tumor control rates achieved through stereotactic radiosurgery are comparable to surgical resection for small, solitary lesions.
Systemic therapeutic modalities are routinely combined with local interventions to eliminate circulating tumor cells and microscopic disease throughout the body. Depending on the primary tumor’s histopathology and genomic alterations, oncologists prescribe targeted biological therapies or modern immune checkpoint inhibitors. Immunotherapy targeting PD-1, PD-L1, or CTLA-4 receptors has demonstrated significant efficacy in managing metastatic pulmonary lesions from various origins. These systemic agents block inhibitory signals that tumors use to evade immune detection, allowing the patient’s immune system to identify and destroy metastatic cells located throughout pulmonary tissue.
Organizing lung metastasis treatment through AlenMed
Arranging specialized oncological care abroad demands rapid communication and careful coordination at every step. Based directly in Munich, AlenMed maintains direct working relationships with senior thoracic surgeons and university oncologists across Germany. The medical team at AlenMed immediately submits high-resolution CT and PET-CT imaging to clinical tumor boards for expert review. Based on this multidisciplinary assessment, the treating hospital generates an official cost estimate (Kostenvoranschlag), detailing transparent pricing for proposed diagnostic and surgical procedures, helping families plan medical expenditures accurately.
AlenMed provides full support with administrative and travel arrangements, issuing official medical invitations from the treating German hospitals to expedite urgent medical visa processing. Upon arrival in Munich, patients are greeted at the airport and provided with comfortable transfer services to their clinic or hotel. Throughout medical consultations, surgical hospitalizations, and follow-up visits, patients are accompanied by a qualified medical interpreter who ensures clear communication with medical staff and provides accurate translations of discharge summaries. Final treatment expenses depend on surgical complexity, intensive care duration, and required systemic medications.
Request a treatment program for lung metastases
If you or a loved one has been diagnosed with secondary lung lesions, you can submit electronic copies of recent CT or PET-CT scans along with medical records through the contact form on the AlenMed website. Our team will arrange a prompt, complimentary preliminary evaluation of your documentation by a multidisciplinary oncology panel in Germany. German specialists will determine surgical resectability, recommend a structured combined treatment plan, and provide an official preliminary cost estimate to help you begin treatment without delay.
The information provided on this page is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Financial estimates and procedure costs are indicative; the final cost of treatment is determined solely by the official cost estimate (Kostenvoranschlag) issued by the treating German hospital after reviewing the patient’s complete medical records.
News on this topic
Activated Regulatory T Cells Tested to Prevent Stem Cell Transplant Complication
German researchers report successful Phase I/II clinical trial results for a novel cell therapy designed to prevent acute graft-versus-host disease in stem cell patients.
Immunotherapy Breakthrough in High-Risk Pediatric Leukemia
A major international study led by UKSH shows replacing aggressive chemo with immunotherapy halves relapse rates and reduces side effects in children with ALL.
CAR T-Cell Therapy Success Linked to Specific Cell Subgroup in New Study
Researchers in Germany have discovered a specific CAR T-cell subgroup that predicts treatment success, offering new hope for personalized cancer immunotherapies.
